Chaoju Eye Care Holdings Limited filed a Next Day Disclosure Return on 17 September 2026 confirming that its issued share capital stood unchanged at 701.46 million ordinary shares as of the same date. No treasury shares were held.

From 31 August to 17 September 2026, the company executed 14 on-market share repurchase transactions that have not yet been cancelled, totalling 2.04 million shares, or 0.29 % of outstanding shares. Repurchase prices ranged between HK$2.38 and HK$2.55 per share.

The most recent buyback occurred on 17 September 2026, when 40,500 shares were acquired on the Hong Kong Stock Exchange at prices between HK$2.435 and HK$2.46, for a consideration of HK$0.10 million.

Under the shareholder mandate approved on 12 May 2026, Chaoju Eye Care is authorised to repurchase up to 70.52 million shares. Cumulative repurchases executed on the Exchange under this mandate have reached 5.38 million shares, equivalent to 0.76 % of the company’s issued share base at the time the mandate was granted.

In accordance with Hong Kong listing rules, Chaoju Eye Care is subject to a moratorium on new share issues or treasury share sales until 17 October 2026.